Search Result

Results for "

LRRK2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	LRRK2 (42) AMPK (2) Apoptosis (1) Aurora Kinase (1) Autophagy (1) BCRP (1) ERK (2) GSK-3 (1) IKK (2) JAK (3) Mitophagy (1) MNK (1) PROTACs (2) Ser/Thr Protease (2) Small Interfering RNA (siRNA) (3) Src (1) Syk (1) VEGFR (1)
By Research Areas:	Cancer (8) Inflammation/Immunology (6) Neurological Disease (36)
Oligonucleotides:	Pre-designed siRNA Sets (3) siRNAs (3)

Inhibitors & Agonists

Screening Libraries

Peptides

Recombinant Proteins

Antibodies

Oligonucleotides

Targets Recommended: LRRK2

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-111493

LRRK2 inhibitor 1	LRRK2	Neurological Disease
LRRK2 inhibitor 1 is a potent, selective and oral *LRRK2* inhibitor with an pIC₅₀ of 6.8.

HY-152107

LRRK2-IN-7	LRRK2	Neurological Disease
LRRK2-IN-7 is a potent, selective, and CNS-penetrant *LRRK2* kinase inhibitor with an IC₅₀ of 0.9 nM. LRRK2-IN-7 shows >1000-fold selectivity over other kinases, ion channels, and CYP enzymes .

HY-RS07833

LRRK2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
LRRK2 Human Pre-designed siRNA Set A contains three designed siRNAs for LRRK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LRRK2 Human Pre-designed siRNA Set A LRRK2 Human Pre-designed siRNA Set A

HY-RS07834

Lrrk2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Lrrk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Lrrk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Lrrk2 Mouse Pre-designed siRNA Set A Lrrk2 Mouse Pre-designed siRNA Set A

HY-RS07835

Lrrk2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Lrrk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Lrrk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Lrrk2 Rat Pre-designed siRNA Set A Lrrk2 Rat Pre-designed siRNA Set A

HY-153058

LRRK2-IN-8	LRRK2 JAK AMPK	Neurological Disease Cancer
LRRK2-IN-8 is a *LRRK2* inhibitor. LRRK2-IN-8 inhibits LRRK2 (wt) and LRRK2 (G2019) with IC₅₀s lower than 10 nM, and inhibits *TYK2* and NUAK1 with IC₅₀s of 10-100 nM .

HY-151441

LRRK2-IN-5	LRRK2	Neurological Disease
LRRK2-IN-5 (compound 25) is a potent, orally active, selective leucine rich repeat protein kinase 2 gene (LRRK2) inhibitor with IC₅₀ values of 1.2 and 16 μM for GS LRRK2 and WT LRRK2, respectively. LRRK2-IN-5 inhibits LRRK2 Ser1292 and Ser925 autophosphorylation. LRRK2-IN-5 can cross the blood-brain barrier .

HY-151444

LRRK2-IN-6	LRRK2	Neurological Disease
LRRK2-IN-6 (compound 22) is a potent, orally active, selective leucine rich repeat protein kinase 2 gene (LRRK2) inhibitor with IC₅₀ values of 4.6 and 49 μM for GS LRRK2 and WT LRRK2, respectively. LRRK2-IN-6 inhibits LRRK2 Ser1292 and Ser925 autophosphorylation. LRRK2-IN-6 can cross the blood-brain barrier .

HY-168041

LRRK2-IN-15	LRRK2 BCRP	Neurological Disease
LRRK2-IN-15 is an *LRRK2* inhibitor. The IC₅₀ value for PBMC cells is 5 nM, and the IC₅₀ value for BCRP is 1.5 μM. LRRK2-IN-15 can be used for research on Parkinson's disease .

HY-161570

LRRK2-IN-12	LRRK2	Neurological Disease
LRRK2-IN-12 (compound 1) inhibits the activity of LRRK2 G20195 (IC₅₀=0.45 nM), LRRK2 WT (IC₅₀=1.1 nM) and LRRK2 WT ADP-Glo (IC₅₀=0.46 nM). LRRK2-IN-12 can be used for Alzheimer's Disease research .

HY-161571

LRRK2-IN-13	LRRK2	Neurological Disease
LRRK2-IN-13 (Compound 13) is an inhibitor of *LRRK2* (IC₅₀=0.57 nM). LRRK2-IN-13 has brain penetrating properties .

HY-10875

LRRK2-IN-1 5+ Cited Publications	LRRK2 Apoptosis	Neurological Disease Cancer
LRRK2-IN-1 is a potent and selective LRRK2* inhibitor* with IC₅₀ of 6 nM and 13 nM for LRRK2 (G2019S) and LRRK2 (WT), respectively.

HY-158365

LRRK2-IN-14	LRRK2	Neurological Disease
LRRK2-IN-14 (Compound 8) is an orally active *LRRK2* inhibitor. LRRK2-IN-14 has an IC₅₀ of 6.3 nM for LRRK2(G2019S) cell activity.LRRK2-IN-14 has an inhibitory effect on hERG (IC₅₀=22 μM). LRRK2-IN-14 has blood-brain barrier permeability .

HY-145317

LRRK2-IN-2	LRRK2	Neurological Disease
LRRK2-IN-2 (compoubd 22) is a potent, selective, orally active and brain-penetrant inhibitor *LRRK2, with IC₅₀* of <0.6 nM. LRRK2-IN-2 can be used for the research of Parkinson's disease .

HY-145318

LRRK2-IN-3	LRRK2	Neurological Disease
LRRK2-IN-3 (compoubd 24) is a potent, selective, orally active and brain-penetrant inhibitor *LRRK2, with IC₅₀* of 2.6 nM in human PBMCs. LRRK2-IN-3 can be used for the research of Parkinson's disease .

HY-156167

LRRK2-IN-10	LRRK2	Neurological Disease
LRRK2-IN-10 (compound 34) is a potent, mutation-selective, and brain penetrant *G2019S-LRRK2* kinase inhibitor with IC₅₀*s of 11 nM and 5.2 nM for G2019S-LRRK2* pS935 and G2019S-LRRK2 pS1292, respectively. LRRK2-IN-10 has the potential for Parkinson's disease research .

HY-144074

LRRK2-IN-4	LRRK2	Neurological Disease
LRRK2-IN-4 is a potent, selective, CNS-penetran and orally active leucine-rich repeat kinase 2 (LRRK2) inhobitor with an IC₅₀ of 2.6 nM. LRRK2-IN-4 has the potential for the research of Parkinson’s disease .

HY-153103

LRRK2/NUAK1/TYK2-IN-1	LRRK2 JAK AMPK	Inflammation/Immunology
LRRK2/NUAK1/TYK2-IN-1 (conpound 226) shows inhibitory activity toward LRRK2 (Wt), LRRK2 (G2019), *TYK2* and NUAK1, with IC₅₀ values lower than 10 nM. LRRK2/NUAK1/TYK2-IN-1 can be used for autoimmune disease research .

HY-152107A

*(R,R)-LRRK2-IN-7*	LRRK2	Neurological Disease
(R,R)-LRRK2-IN-7 is the isomer of LRRK2-IN-7 (HY-152107). LRRK2-IN-7 is a potent, selective, and CNS-penetrant LRRK2 kinase inhibitor with an IC50 of 0.9 nM. LRRK2-IN-7 shows >1000-fold selectivity over other kinases, ion channels, and CYP enzymes.

HY-B0792

CZC-54252	LRRK2	Neurological Disease
CZC-54252 is a potent and selective *LRRK2* inhibitor with IC₅₀s of 1.28 nM and 1.85 nM for wild-type and G2019S LRRK2, respectively. CZC-54252 attenuates G2019S LRRK2-induced human neuronal injury with an EC₅₀ of ~1 nM. CZC-54252 has a neuroprotective activity .

HY-B0792A

CZC-54252 hydrochloride	LRRK2	Neurological Disease
CZC-54252 hydrochloride is a potent and selective *LRRK2* inhibitor with IC₅₀s of 1.28 nM and 1.85 nM for wild-type and G2019S LRRK2, respectively. G2019S LRRK2-induced human neuronal injury is attenuated by CZC-54252 hydrochloride with an EC₅₀ of ~1 nM.CZC-54252 hydrochloride has a neuroprotective activity .

HY-162699

LY2023-001	LRRK2	Neurological Disease
LY2023-001 is a potent G2019S LRRK2 inhibitor with an IC₅₀ of 12.9 nM. LY2023-001 formed stable hydrogen bonds with Glu1948, and Ala1950 in the G2019S LRRK2 protein .

HY-112855

PF-06454589	LRRK2	Neurological Disease
PF-06447475 is a highly potent, selective, brain penetrant LRRK2 kinase inhibitor with IC₅₀ values of 3 nM and 11 nM for WT LRRK and G2019S LRRK2, respectively. PF-06447475 can be used for parkinson's disease (PD) research .

HY-15800A

CZC-25146	LRRK2	Neurological Disease Inflammation/Immunology
CZC-25146 is a potent and orally active *LRRK2* inhibitor with IC₅₀ values of 4.76 nM and 6.87 nM for wild-type LRRK2 and G2019S LRRK2, respectively. CZC-25146 inhibits PLK4, GAK, TNK1, CAMKK2 and PIP4K2C as well. CZC-25146 prevents mutant LRRK2-induced injury of neurons in vitro. CZC-25146 exhibits relatively favorable pharmacokinetic properties in mice. CZC-25146 can increase normal α-1-antitrypsin (AAT) secretion and reduce inflammatory cytokines. CZC-25146 can be used to research Parkinson's disease and liver diseases ^[2] .

HY-15800

CZC-25146 hydrochloride	LRRK2	Neurological Disease Inflammation/Immunology
CZC-25146 hydrochloride is a potent *LRRK2* inhibitor with IC₅₀ values of 4.76 nM and 6.87 nM for wild-type LRRK2 and G2019S LRRK2, respectively. CZC-25146 hydrochloride inhibits PLK4, GAK, TNK1, CAMKK2 and PIP4K2C as well. CZC-25146 hydrochloride prevents mutant LRRK2-induced injury of neurons in vitro. CZC-25146 hydrochloride exhibits relatively favorable pharmacokinetic properties in mice. CZC-25146 hydrochloride can increase normal α-1-antitrypsin (AAT) secretion and reduce inflammatory cytokines. CZC-25146 hydrochloride can be used to research Parkinson's disease and liver diseases ^[2] .

HY-12282

GNE-9605	LRRK2	Neurological Disease
GNE-9605 is a potent, orally active, selective Leucine-rich repeat kinase 2 (LRRK2) inhibitor with an IC₅₀ value of 18.7 nM. GNE-9605 inhibits LRRK2 Ser1292 autophosphorylation. GNE-9605 can be used in research of Parkinson's disease (PD) .

HY-155150

JH-XII-03-02	LRRK2 PROTACs	Cancer
JH-XII-03-02 is a potent and selective LRRK2 PROTAC degrader. JH-XII-03-02 can be used for parkinson's Disease (PD) research .

HY-148030

XL01126	PROTACs LRRK2	Neurological Disease
XL01126 is a potent *LRRK2* PROTAC (DC₅₀: 14 nM (G2019S *LRRK2) and 32 nM (WT LRRK2)) composed of the VHL ligand VH 101, thiol (HY-47851, blue part) and the LRRK2* inhibitor HG-10-102-01 (HY-13488, red part). XL01126 crosses the blood-brain barrier and is used as a degradation probe in Parkinson's disease research. XL01126 can be used to study the non-catalytic and framework functions of *LRRK2* .

HY-16936

JH-II-127	LRRK2	Neurological Disease
JH-II-127 is an orally active, highly potent, selective and brain-permeable *LRRK2* inhibitor, with IC₅₀s of 6, 2 and 48 nM for wild-type *LRRK2* and *LRRK2-G2019S* and mutant *LRRK2-A2016T. JH-II-127 inhibits Ser935* phosphorylation in all tissues of mice, including the brain. JH-II-127 can be used in the study of parkinson's syndrome .

HY-108886

JWG-071 3 Publications Verification	ERK	Cancer
JWG-071 is the kinase-selective chemical probe for ERK5. JWG-071 inhibits ERK5 and LRRK2 with IC₅₀ values of 88nM and 109 nM, respectively .

HY-156429

MK-1468	LRRK2	Neurological Disease
MK-1468 is a high selective and brain-penetrant inhibitor of *LRRK2* with an IC₅₀ of 0.8 nM. MK-1468 can be used in study Parkinson’s disease .

HY-P10636

Nictide	LRRK2	Others
Nictide is a peptide substrate of LRRK2 (leucine-rich repeat protein kinase-2). Nictide can be phosphorylated by the activated LRRK2[G2019S] with a Km of 10 μM .

HY-13237

GSK2578215A 2 Publications Verification	LRRK2 Autophagy Mitophagy	Neurological Disease Cancer
GSK2578215A is a potent and highly selective *LRRK2* inhibitor, which exhibits IC₅₀s of around 10 nM against both wild-type LRRK2 and the G2019S mutant.

HY-13488

HG-10-102-01 1 Publications Verification	LRRK2 MNK	Neurological Disease
HG-10-102-01 is a highly potent, selective, and brain-penetrable *LRRK2* inhibitor, with IC₅₀ values of 20.3 and 3.2 nM against wild-type LRRK2 and *LRRK2[G2019S], respectively. HG-10-102-01 also inhibits MNK2* and MLK1, with IC₅₀ values of 0.6 and 2.1 μM. HG-10-102-01 can be used for Parkinson's disease (PD) research ^[2].

HY-18163

GNE-7915 5+ Cited Publications	LRRK2	Neurological Disease
GNE-7915 is a potent, selective and brain-penetrant inhibitor of *LRRK2* with an IC₅₀ of 9 nM.

HY-18163A

GNE-7915 tosylate 5+ Cited Publications	LRRK2	Neurological Disease
GNE-7915 tosylate is a potent, selective and brain-penetrant inhibitor of *LRRK2* with an IC₅₀ of 9 nM.

HY-12477

PF-06447475 3 Publications Verification	LRRK2	Neurological Disease
PF-06447475 is a highly potent, selective and brain penetrant *LRRK2* inhibitor with an IC₅₀ of 3 nM.

HY-134562

PF-06371900	LRRK2	Neurological Disease
PF-06371900 is a potent and highly selective leucine rich repeat kinase 2 (LRRK2) inhibitor .

HY-142647

EB-42486	LRRK2	Neurological Disease
EB-42486 is a novel, potent, and highly selective *G2019S-LRRK2* inhibitor (IC₅₀ < 0.2 nM).

HY-14403

ERK5-IN-1	ERK	Cancer
ERK5-IN-1 is a potent ERK5 inhibitor with an IC₅₀ of 87±7 nM. ERK5-IN-1 also inhibits *LRRK2*[G2019S] with an IC₅₀ of 26 nM.

HY-15796

GNE0877 2 Publications Verification	LRRK2	Neurological Disease
GNE0877 is a highly selective, orally active and brain-penetrant *LRRK2* inhibitor with an IC₅₀ of 3 nM and a K_i of 0.7 nM. GNE0877 can be used for the research of neuroscience .

HY-100411

MLi-2 5+ Cited Publications	LRRK2	Neurological Disease
MLi-2 is an orally active and highly selective *LRRK2* inhibitor with an IC₅₀ of 0.76 nM. MLi-2 has the potential for Parkinson’s disease .

HY-120085

PFE-360 2 Publications Verification PF-06685360	LRRK2	Neurological Disease
PFE-360 (PF-06685360) is a potent, selective, brain penetrated and orally active leucine-rich repeat kinase 2 (LRRK2) inhibitor with a mean IC₅₀ of 2.3 nM in vivo ^[2].

HY-13687

IKK 16 Maximum Cited Publications 16 Publications Verification	IKK LRRK2	Inflammation/Immunology
IKK 16 is a selective IκB kinase (IKK) inhibitor for *IKK2, IKK complex* and IKK1 with IC₅₀s of 40 nM, 70 nM and 200 nM, respectively. IKK16 also inhibits leucine-rich repeat kinase-2 (LRRK2) with an IC₅₀ of 50 nM.

HY-148353

PF-06455943	LRRK2	Neurological Disease
PF-06455943 is a leucine rich repeat kinase 2 (LRRK2) inhibitor with IC₅₀ value of 3 nM. PF-06455943 also is a PET radioligand. PF-06455943 can be used for the research of ADME/neuro PK characterization and Parkinson disease (PD) ^[2].

HY-13687A

IKK 16 hydrochloride Maximum Cited Publications 16 Publications Verification	IKK LRRK2	Inflammation/Immunology
IKK 16 hydrochloride is a selective IκB kinase (IKK) inhibitor for *IKK2, IKK complex* and IKK1 with IC₅₀s of 40 nM, 70 nM and 200 nM, respectively . IKK16 also inhibits leucine-rich repeat kinase-2 (LRRK2) with an IC₅₀ of 50 nM ^[2].

HY-112809

GSK2646264	Syk Src LRRK2 GSK-3 JAK VEGFR Aurora Kinase	Inflammation/Immunology
GSK2646264 (Compound 44) is a potent and selective spleen tyrosine kinase (SYK) inhibitor with a pIC₅₀ of 7.1. GSK2646264 also inhibits other kinases with pIC₅₀ values of 5.4, 5.4, 5.3, 5, 4.5, <4.6 and <4.3 against LCK, *LRRK2, GSK3β, JAK2, VEGFR2, Aurora B* and Aurora A, respectively. GSK2646264 is penetrable into the epidermis and dermis of the skin .

HY-163184

DCLK1-IN-3	Ser/Thr Protease	Cancer
DCLK1-IN-3 is a potent and selective doublecortin-like kinase 1 (DCLK1) inhibitor with an IC₅₀ of 47 nM. DCLK1-IN-3 can be used for the research of cancer .

HY-163185

DCLK1-IN-4	Ser/Thr Protease	Cancer
DCLK1-IN-4 (compound D2) is a potent and selective doublecortin-like kinase 1 (DCLK1) inhibitor with an IC₅₀ of 70 nM. DCLK1-IN-4 can be used for the research of cancer .

Cat. No.	Product Name

HY-L029

Autophagy Compound Library

1,435 compounds

Autophagy is a lysosomal degradation pathway that is essential for cell survival, differentiation, development, and homeostasis. The process of autophagy in mammalian cells is as follows: a portion of cytoplasm, including organelles, is enclosed by a phagophore or isolation membrane to form an autophagosome. The outer membrane of the autophagosome subsequently fuses with the endosome and then the lysosome, and the internal material is degraded. Autophagy plays a wide variety of physiological and pathophysiological roles. Defective autophagy contributes to various pathologies, including infections, cancer, neurodegeneration, aging, and heart disease.

MCE provides a unique collection of 1,435 autophagy pathway-related compounds that is a useful tool for the research of autophagy-related regulation and diseases.

HY-L085

Anti-Parkinson's Disease Compound Library

1,466 compounds

Parkinson’s disease (PD), the second most common age-associated neurodegenerative disorder, is characterized by the loss of dopaminergic (DA) neurons and the presence of α-synuclein-containing aggregates in the substantia nigra pars compacta (SNpc). Motor features such as tremor, rigidity, bradykinesia and postural instability are common traits of PD. To date, there is no treatment to stop or at least slow down the progression of the disease. The etiology and pathogenesis of PD is still elusive, however, a large body of evidence suggests a prominent role of oxidative stress, inflammation, apoptosis, mitochondrial dysfunction and proteasome dysfunction in the pathogenesis of PD.

MCE offers a unique collection of 1,466 compounds with anti- Parkinson’s Disease activities or targeting the unique targets of PD. MCE Anti- Parkinson's Disease Compound Library is a useful tool for exploring the mechanism of PD and discovering new drugs for PD.

HY-L086

Neurodegenerative Disease-related Compound Library

2,435 compounds

Neurodegenerative diseases are incurable and life-threatening conditions that result in progressive degeneration and/or death of nerve cells. Some common neurodegenerative diseases include Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Motor Neuron Disease (MND), Huntington’s Disease (HD), Spino-Cerebellar Ataxia (SCA), Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS). Because the pathophysiology of neurodegenerative disorders is generally poorly understood, it is difficult to identify promising molecular targets and validate them. At the same time, about 85% of the drugs fail in clinical trials. Therefore, validating new targets and discovering new drugs to mitigate neurodegenerative disorders is need of the hour.

MCE offers a unique collection of 2,435 compounds with anti-Neurodegenerative Diseases activities or targeting the unique targets of neurodegenerative diseases. MCE Neurodegenerative Disease-related Compound Library is a useful tool for exploring the mechanism of neurodegenerative diseases and discovering new drugs for neurodegenerative diseases.

Cat. No.	Product Name	Target	Research Area

HY-P10636

Nictide	LRRK2	Others
Nictide is a peptide substrate of LRRK2 (leucine-rich repeat protein kinase-2). Nictide can be phosphorylated by the activated LRRK2[G2019S] with a Km of 10 μM .

Species:	Human (2)
Tag:	His (2) Strep (2) GST (2)
Source:	Sf9 insect cells (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P703643

	LRRK2 Protein, Human (Inactive, Sf9, GST, Strep, His) PARK8	Human	Sf9 insect cells
	LRRK2 Protein, Human (Inactive, Sf9, GST, Strep, His) is the recombinant human-derived LRRK2, expressed by Sf9 insect cells , with Strep, His, GST labeled tag. ,

HY-P703644

	LRRK2 Protein, Human (Sf9, GST, Strep, His, G2019S) PARK8	Human	Sf9 insect cells
	LRRK2 Protein, Human (Sf9, GST, Strep, His, G2019S) is the recombinant human-derived LRRK2, expressed by Sf9 insect cells , with Strep, His, GST labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83076

	LRRK2 Antibody (YA2821) AURA17; Dardarin antibody; ; Leucine rich repeat kinase 2; LRRK 2 antibody; LRRK2; LRRK2_HUMAN; PARK 8; PARK8; RIPK7; ROCO 2; ROCO2	WB, IHC-P, ICC/IF	Human, Mouse
	LRRK2 Antibody (YA2821) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2821), targeting LRRK2, with a predicted molecular weight of 286 kDa (observed band size: 286 kDa). LRRK2 Antibody (YA2821) can be used for WB, IHC-P, ICC/IF experiment in human, mouse background.

HY-P83076A

	*Phospho-LRRK2(Ser935) Antibody* AURA17; Dardarin antibody; ; Leucine rich repeat kinase 2; LRRK 2 antibody; LRRK2; LRRK2_HUMAN; PARK 8; PARK8; RIPK7; ROCO 2; ROCO2	WB, ICC/IF	Human, Mouse
	Phospho-LRRK2(Ser935) Antibody is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3424), targeting LRRK2, with a predicted molecular weight of 286 kDa (observed band size: 286 kDa). Phospho-LRRK2(Ser935) Antibody can be used for WB,ICC/IF experiment in human, mouse background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: